{"brief_title": "Monotherapy Versus Placebo Over 7 Days-Non-Nucleoside Reverse Transcriptase Inhibitor-Experienced HIV1 Infected Adults", "brief_summary": "To investigate safety, tolerability and antiviral activity in Non-nucleoside reverse transcriptase inhibitor (NNRTI)-experienced HIV-1 infected patients", "condition": "HIV Infections", "intervention_type": "Drug", "intervention_name": "GW695634", "criteria": "Inclusion criteria: - CD4 cell count greater than or equal to 200 cells/mm3. - HIV-1 RNA >2000 copies/mL. - Must have history of NNRTI treatment with subsequent failure and documented evidence of an NNRTI-associated mutation or a phenotype displaying reduced activity to efavirenz, nevirapine or delavirdine. - Normal resting 12-lead electrocardiogram. Exclusion criteria: - Any history of seizure, CNS toxoplasmosis infection, or any CNS (central nervous system) lesion. - Chronic diarrhea (>3 loose stools/day). - An active CDC Category C disease (1993), except cutaneous Kaposi's Sarcoma (KS) not requiring systemic therapy during the trial. - Less than 4 weeks since stopping anti-retroviral therapy (ART) therapy prior to Day 1. - Any acute laboratory abnormality. - Positive for HCV antibody or HepBsAG. - Active infections requiring therapy in the previous 4 weeks.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00090077.xml"}